• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
Prostaglandins Other Lipid Mediat. 2023 Jul 19:106766. doi: 10.1016/j.prostaglandins.2023.106766. Online ahead of print.ABSTRACTPlatelets are one of the key mediators in thrombosis as well as in the progression of many diseases. An increase in platelet activation and a decrease in platelet count is associated with a plethora of liver diseases. In non-alcoholic fatty liver disease (NAFLD), platelets are highly activated and participate in the disease progression by enhancing the pro-thrombotic and pro-inflammatory state. Some altered platelet parameters such as mean platelet volume, plateletcrits, and platelet distribution ...
Source: Atherosclerosis - July 21, 2023 Category: Cardiology Authors: Malladi Navya Md Jahangir Alam Subir K Maulik Sanjay K Banerjee Source Type: research

Antiplatelets and Vascular Dementia: A Systematic Review
J Aging Res. 2022 Sep 19;2022:9780067. doi: 10.1155/2022/9780067. eCollection 2022.ABSTRACTVascular dementia (VD) is a neurocognitive disorder whose precise definition is still up for debate. VD generally refers to dementia that is primarily caused by cerebrovascular disease or impaired cerebral blood flow. It is a subset of vascular cognitive impairment, a class of diseases that relate any cerebrovascular injury as a causal or correlating factor for cognitive decline, most commonly seen in the elderly. Patients who present with both cognitive impairment and clinical or radiologic indications of cerebrovascular pathology s...
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Peter Alexander Shakthi Visagan Sara Jawhar Amogh Kare Noor Issa Reem Issa Abbas Jawhar Sneha Thomas Vasavi Gorantla Source Type: research

A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
In conclusion, these results suggest cilostazol may have beneficial effects in patients with CAD or at a high risk of CV disease.PMID:35743723 | DOI:10.3390/jpm12060938
Source: Atherosclerosis - June 24, 2022 Category: Cardiology Authors: Jia-Ling Lin Wei-Kung Tseng Po-Tseng Lee Cheng-Han Lee Shih-Ya Tseng Po-Wei Chen Hsien-Yuan Chang Ting-Hsing Chao Source Type: research

Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis
CONCLUSIONS: The efficacy and safety profiles among antiplatelet regimens may differ according to clinical situation, although cilostazol, aspirin plus clopidogrel, and aspirin plus dipyridamole may be considered as preferable options.PMID:35402589 | PMC:PMC8987873 | DOI:10.21037/atm-21-3748
Source: Atherosclerosis - April 11, 2022 Category: Cardiology Authors: Seung Jin Jung Bum Joon Kim Chi Kyung Kim Sung Ryul Shim Jin-Man Jung Source Type: research

Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
Stroke Vasc Neurol. 2022 Apr 7:svn-2021-001166. doi: 10.1136/svn-2021-001166. Online ahead of print.ABSTRACTAntiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-antiplatelet therapy ...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Jay Shah Shimeng Liu Wengui Yu Source Type: research